Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carboplatin, Gemcitabine, and Exisulind in Advanced NSCLC
NCT00041314Phase 2Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Oct 2002
- Primary completion
- Jul 2005
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 2, open-label, single-arm trial of exisulind in non-small cell lung cancer (NSCLC), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: 18-Month Survival Rate. Started Oct 2002; status: completed.
02
Drugs
exisulind
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00041314.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00041314.